ImmuCell Corporation: net inventory
ImmuCell net inventory: $9.27 million at 2025-12-31, up 30.3% on the year. 16 values since 2010 from SEC filings, each linked to its filing. In original units.
All ImmuCell Corporation financial histories
At a glance
ImmuCell reported net inventory of $9.27 million at 2025-12-31, up 30.3% from $7.11 million a year earlier. From 2010 to 2025 it grew at a compound 12.4% a year, from $1.60 million to $9.27 million. Across the last five reported years it ranged from $3.09 million (2021-12-31) to $9.27 million (2025-12-31). That was 21.8% of total assets ($42.5 million) at the same date.
Computed from the values in the table below, in USD; each links to the filing it came from.
What this measure means
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
Exact concept: us-gaap:InventoryNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-12-31 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| - | 2025-12-31 | 9,267,369 | USD | 2026-03-30 | 10-K · 0001437749-26-010339 SEC |
| - | 2024-12-31 | 7,112,623 | USD | 2026-03-30 | 10-K · 0001437749-26-010339 SEC |
| - | 2023-12-31 | 7,811,841 | USD | 2025-03-28 | 10-K · 0001013762-25-004072 SEC |
| - | 2022-12-31 | 6,038,539 | USD | 2024-04-01 | 10-K · 0001213900-24-028718 SEC |
| - | 2021-12-31 | 3,089,974 | USD | 2023-03-29 | 10-K · 0001213900-23-024080 SEC |
| - | 2020-12-31 | 2,092,514 | USD | 2022-03-30 | 10-K · 0001213900-22-016147 SEC |
| - | 2019-12-31 | 2,518,256 | USD | 2021-03-30 | 10-K · 0001213900-21-018473 SEC |
| - | 2018-12-31 | 2,331,671 | USD | 2020-03-27 | 10-K · 0001213900-20-007650 SEC |
| - | 2017-12-31 | 2,049,732 | USD | 2019-03-22 | 10-K · 0001213900-19-004653 SEC |
| - | 2016-12-31 | 2,126,899 | USD | 2018-03-29 | 10-K · 0001213900-18-003621 SEC |
| - | 2015-12-31 | 870,207 | USD | 2017-03-30 | 10-K · 0001213900-17-003009 SEC |
| - | 2014-12-31 | 945,755 | USD | 2016-03-25 | 10-K · 0001213900-16-011870 SEC |
| - | 2013-12-31 | 1,206,508 | USD | 2015-03-26 | 10-K · 0001213900-15-002097 SEC |
| - | 2012-12-31 | 1,649,002 | USD | 2014-03-26 | 10-K · 0001144204-14-017813 SEC |
| - | 2011-12-31 | 1,666,465 | USD | 2013-03-28 | 10-K · 0001144204-13-018264 SEC |
| - | 2010-12-31 | 1,601,016 | USD | 2012-03-27 | 10-K · 0001144204-12-017287 SEC |
Related ImmuCell Corporation histories
Inspect the source
- Entity
- ImmuCell Corporation / CIK 0000811641
- Captured
- SEC response SHA-256
e6fd54c346f29af23b63003a8b733aa2d9275cd6689854dc3a6eebcd0ca809e7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000811641.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))